Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAPNASDAQ:GUTSNASDAQ:NEPHNYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEdap Tms$1.60+1.6%$1.86$1.26▼$5.27$59.45MN/A98,917 shs22,749 shsGUTSFractyl Health$1.64-0.3%$1.80$0.87▼$4.92$80.81M1.58368,117 shs149,311 shsNEPHNephros$4.08+2.5%$3.04$1.36▼$5.00$42.72M1.0917,966 shs19,108 shsNSPRInspireMD$2.26+1.1%$2.43$1.99▼$3.80$69.08M0.5766,751 shs44,755 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEdap Tms0.00%-4.49%-11.88%-0.93%-69.62%GUTSFractyl Health0.00%-0.30%-15.72%+45.98%-63.42%NEPHNephros0.00%+5.70%+20.00%+100.00%+96.63%NSPRInspireMD0.00%-1.53%-9.80%-14.58%-7.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDAPEdap Tms2.3844 of 5 stars3.25.00.00.00.01.70.6GUTSFractyl Health2.0192 of 5 stars3.53.00.00.01.10.00.0NEPHNephros0.8514 of 5 stars2.53.00.00.00.00.80.0NSPRInspireMD3.3936 of 5 stars3.54.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEdap Tms 2.33Hold$8.50432.92% UpsideGUTSFractyl Health 3.00Buy$11.00572.78% UpsideNEPHNephros 3.00Buy$5.0022.55% UpsideNSPRInspireMD 3.00Buy$4.5099.56% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, EDAP, GUTS, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025EDAPEdap TmsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.004/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEdap Tms$69.18M0.86N/AN/A$1.18 per share1.35GUTSFractyl Health$60K1,334.62N/AN/A$0.59 per share2.77NEPHNephros$14.16M3.05$0.02 per share201.39$0.81 per share5.04NSPRInspireMD$7.03M9.83N/AN/A$1.83 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEdap Tms-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)GUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)NEPHNephros$70K$0.0758.29∞N/A5.16%9.43%7.20%8/6/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest NEPH, EDAP, GUTS, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025EDAPEdap Tms-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEdap TmsN/AN/AN/AN/AN/AGUTSFractyl HealthN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEdap Tms0.101.741.21GUTSFractyl Health4.612.502.50NEPHNephrosN/A5.924.64NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEdap Tms62.74%GUTSFractyl HealthN/ANEPHNephros41.10%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipEDAPEdap Tms0.23%GUTSFractyl HealthN/ANEPHNephros6.70%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEdap Tms23037.39 million37.31 millionOptionableGUTSFractyl Health10248.98 millionN/AN/ANEPHNephros3010.60 million9.89 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionableNEPH, EDAP, GUTS, and NSPR HeadlinesRecent News About These CompaniesInspireMD, Inc. (NSPR) Latest Stock News & Headlines - Yahoo FinanceJuly 5 at 10:22 PM | finance.yahoo.comHuntleigh Advisors Inc. Makes New $316,000 Investment in InspireMD, Inc. (NYSE:NSPR)July 5 at 6:35 AM | marketbeat.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - MorningstarJune 26, 2025 | morningstar.comMInspireMD Inc.: InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of StrokeJune 25, 2025 | finanznachrichten.deFDA grants PMA for InspireMD CGuard Prime carotid stent, triggers $18M milestone paymentJune 25, 2025 | massdevice.comInspireMD Stock Surges on FDA Approval for CGuard StentJune 24, 2025 | marketwatch.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of StrokeJune 24, 2025 | globenewswire.comInspireMD CGuard Prime EPS Carotid Stent System Receives CE Mark ApprovalJune 16, 2025 | evtoday.comEInspireMD Announces CE Mark Approval For CGuard Prime Embolic Prevention SystemJune 15, 2025 | nasdaq.comInspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent SystemJune 15, 2025 | nasdaq.comInspireMD wins CE Mark approval for CGuard PrimeJune 13, 2025 | massdevice.comInspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of StrokeJune 13, 2025 | globenewswire.comInspireMD Hires New Financial ChiefJune 4, 2025 | marketwatch.comInspireMD appoints Michael Lawless CFOJune 4, 2025 | msn.comInspireMD Announces Appointment of Michael Lawless as Chief Financial OfficerJune 3, 2025 | globenewswire.comInspireMD at Bank of America 2025: Carotid Stent InnovationMay 15, 2025 | uk.investing.comEarnings call transcript: InspireMD Q1 2025 shows mixed resultsMay 11, 2025 | uk.investing.comInspireMD, Inc. Reports Q1 2025 Financial Results and Anticipates FDA Approval for CGuard™ Prime Carotid Stent SystemMay 11, 2025 | nasdaq.comInspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comInspireMD Inc.: InspireMD Reports First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deINSPIREMD Earnings Preview: Recent $NSPR Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEPH, EDAP, GUTS, and NSPR Company DescriptionsEdap Tms NASDAQ:EDAP$1.60 +0.03 (+1.59%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.Fractyl Health NASDAQ:GUTS$1.64 -0.01 (-0.30%) Closing price 07/3/2025 03:36 PM EasternExtended Trading$1.64 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.Nephros NASDAQ:NEPH$4.08 +0.10 (+2.51%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.InspireMD NYSE:NSPR$2.26 +0.03 (+1.12%) Closing price 07/3/2025 02:56 PM EasternExtended Trading$2.26 0.00 (0.00%) As of 07/3/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
